Screener
Inhibrx Biosciences, Inc. INBX Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed August 13, 2026.
- Filed
- Aug 13, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0002007919-26-000042
| Line item | THREE MONTHS ENDEDJUNE 30, 2026 | THREE MONTHS ENDEDJUNE 30, 2025 | SIX MONTHS ENDEDJUNE 30, 2026 | SIX MONTHS ENDEDJUNE 30, 2025 |
|---|---|---|---|---|
| Revenue: | ||||
| License fee revenue | — | $1,300 | — | $1,300 |
| Total revenue | — | 1,300 | — | 1,300 |
| Operating expenses: | ||||
| Research and development | 23,899 | 22,267 | 49,116 | 59,144 |
| General and administrative | 8,250 | 6,422 | 13,960 | 12,446 |
| Total operating expenses | 32,149 | 28,689 | 63,076 | 71,590 |
| Loss from operations | (32,149) | (27,389) | (63,076) | (70,290) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Inhibrx Biosciences, Inc.'s total revenue?
- Inhibrx Biosciences, Inc. (INBX) reported total revenue of $0 in Q2 2026.
- How has Inhibrx Biosciences, Inc.'s total revenue changed year-over-year?
- Inhibrx Biosciences, Inc.'s total revenue decreased by 100.0% year-over-year, from $1.3M to $0.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s total revenue?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s total revenue has grown at a -15.0% compound annual growth rate (CAGR), from $1.8M to $1.3M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Inhibrx Biosciences, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude